

ASX RELEASE (21 NOVEMBER 2023)

Epsilon Healthcare announces Termination of Chief Executive Officer

Dear Shareholders.

Epsilon Healthcare Limited (ASX:EPN), effective immediately at 3:35pm 21 November 2023, terminates Mr Peter Giannopoulos as the role of the Chief Executive Officer. Mr Giannopoulos did not complete his probationary period.

This decision aligns with the terms and conditions outlined in the employment contract, specifically regarding the clause Probation.

As we navigate through this transition, we want to assure our stakeholders that the Board remains committed to the success of EPN. In the interim, Mr Daniel Sanghera, General Manager at Epsilon Pharma will become the interim CEO.

We appreciate the understanding and support of our shareholders, employees, and the public during this period of change. Our commitment to delivering value and maintaining the strong performance of our company remains unwavering.

Thank you for your continued trust.

This announcement has been approved for release by the Board of Director

ENDS

For further information, please contact:

Josh Cui Chairman

e: corporate@epsilonhealthcare.com.au

Epsilon Healthcare Limited (ASX: EPN) – epsilonhealthcare.com.au

Epsilon Healthcare Limited (ASX: EPN) is an Australian based, globally active healthcare organisation. EPN operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation & a pharmaceutical contract development and manufacturing organisation.



Epsilon Healthcare Limited (ASX: EPN) ACN: 614 508 039